How to Safely Deliver Stereotactic Ablative Radiotherapy With High-Dose or Multi-agent Systemic Therapy

SABR given concurrently with multi-agent and high-dose systemic therapy during the off week of therapy is a safe and efficacious option. This treatment technique allows patients to remain on systemic therapy without any interruptions. Therefore, SABR can be a preferred local ablative treatment for patients with oligometastatic and oligoprogressive cancer while on concurrent systemic therapy.